152 related articles for article (PubMed ID: 23143159)
1. Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus: a multicenter study.
Tribouilloy C; Rusinaru D; Maréchaux S; Jeu A; Ederhy S; Donal E; Réant P; Arnalsteen E; Boulanger J; Ennezat PV; Garban T; Jobic Y
Circulation; 2012 Dec; 126(24):2852-8. PubMed ID: 23143159
[TBL] [Abstract][Full Text] [Related]
2. Frequency of drug-induced valvular heart disease in patients previously exposd to benfluorex: a multicentre prospective study.
Tribouilloy C; Maréchaux S; Jobic Y; Jeu A; Ederhy S; Donal E; Réant P; Arnalsteen E; Boulanger J; Garban T; Ennezat PV; Andréjak M; Rusinaru D
Eur Heart J; 2013 Dec; 34(46):3580-7. PubMed ID: 24014218
[TBL] [Abstract][Full Text] [Related]
3. [Benfluorex and valvular heart disease].
Tribouilloy C; Jeu A; Maréchaux S; Jobic Y; Rusinaru D; Andréjak M
Presse Med; 2011 Nov; 40(11):1008-16. PubMed ID: 21981882
[TBL] [Abstract][Full Text] [Related]
4. Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: a multicentre study.
Maréchaux S; Jeu A; Jobic Y; Ederhy S; Donal E; Réant P; Abouth S; Arnasteen E; Boulanger J; Ennezat PV; Garban T; Szymanski C; Tribouilloy C
Arch Cardiovasc Dis; 2013; 106(6-7):349-56. PubMed ID: 23876809
[TBL] [Abstract][Full Text] [Related]
5. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus.
Weill A; Païta M; Tuppin P; Fagot JP; Neumann A; Simon D; Ricordeau P; Montastruc JL; Allemand H
Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1256-62. PubMed ID: 20945504
[TBL] [Abstract][Full Text] [Related]
6. [About the settlement of litigations concerning the harm caused by benfluorex (Mediator®)].
Nicot P; Frachon I; Hill C
Presse Med; 2013 Apr; 42(4 Pt 1):411-8. PubMed ID: 23490638
[TBL] [Abstract][Full Text] [Related]
7. How can benfluorex-related heart valve disease be identified by echocardiography?
Tribouilloy C; Rusinaru D; Andréjak M
Arch Cardiovasc Dis; 2011 Oct; 104(10):489-92. PubMed ID: 22044700
[No Abstract] [Full Text] [Related]
8. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
[TBL] [Abstract][Full Text] [Related]
9. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL
JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT
N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086
[TBL] [Abstract][Full Text] [Related]
11. Food and Drug Administration criteria for the diagnosis of drug-induced valvular heart disease in patients previously exposed to benfluorex: a prospective multicentre study.
Maréchaux S; Rusinaru D; Jobic Y; Ederhy S; Donal E; Réant P; Arnalsteen E; Boulanger J; Garban T; Ennezat PV; Jeu A; Szymanski C; Tribouilloy C
Eur Heart J Cardiovasc Imaging; 2015 Feb; 16(2):158-65. PubMed ID: 25368209
[TBL] [Abstract][Full Text] [Related]
12. Restrictive organic mitral regurgitation associated with benfluorex therapy.
Tribouilloy C; Rusinaru D; Henon P; Tribouilloy L; Leleu F; Andréjak M; Sevestre H; Peltier M; Caus T
Eur J Echocardiogr; 2010 Aug; 11(7):614-21. PubMed ID: 20237052
[TBL] [Abstract][Full Text] [Related]
13. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.
Mast ST; Jollis JG; Ryan T; Anstrom KJ; Crary JL
Ann Intern Med; 2001 Feb; 134(4):261-6. PubMed ID: 11182835
[TBL] [Abstract][Full Text] [Related]
14. Operative finding of aortic cusp prolapse in benfluorex-induced aortic regurgitation.
Ennezat PV; Bruneval P; Maréchaux S; Bellemin JP; Senellart F; Arnaud-Crozat E; Ramadan R; Obadia JF; Touati G; Fleury JP; Tribouilloy C
Int J Cardiol; 2015; 186():231-2. PubMed ID: 25828122
[No Abstract] [Full Text] [Related]
15. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
N Engl J Med; 1998 Sep; 339(11):725-32. PubMed ID: 9731088
[TBL] [Abstract][Full Text] [Related]
16. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.
Kancherla MK; Salti HI; Mulderink TA; Parker M; Bonow RO; Mehlman DJ
Am J Cardiol; 1999 Dec; 84(11):1335-8. PubMed ID: 10614800
[TBL] [Abstract][Full Text] [Related]
17. Calcifications in benfluorex-induced valve heart disease: a misknown association.
Plurien F; Bruneval P; Jobic Y; Iung B; Ennezat PV
Cardiology; 2015; 130(2):87-90. PubMed ID: 25614032
[TBL] [Abstract][Full Text] [Related]
18. Benfluorex: lesions on a bioprosthetic heart valve too.
Prescrire Int; 2012 Oct; 21(131):240-1. PubMed ID: 23189378
[No Abstract] [Full Text] [Related]
19. Clinical and echographic characteristics of patients exposed to fenfluramin or its derivatives: Results of a prospective, single-centre, observational study.
Cambon D; Leclercq F
Arch Cardiovasc Dis; 2015 Mar; 108(3):172-80. PubMed ID: 25754908
[TBL] [Abstract][Full Text] [Related]
20. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs.
Burger AJ; Charlamb MJ; Singh S; Notarianni M; Blackburn GL; Sherman HB
Int J Cardiol; 2001 Jul; 79(2-3):159-65. PubMed ID: 11461737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
